CHGCF News and Press, Chugai Pharmaceutical From 07/27/20

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2020 Q2 earnings Read more ...

The value of proper clinical trials is that they give results that give confidence in the efficacy (or otherwise) of drugs. The UK has a complex major trial (RECOVERY) for testing drugs for treating COVID-19. Recent results from this trial were pivotal in the FDA deciding that hydroxychloro...

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2020 Results Conference Call April 23, 2020 05:00 AM ET Company Participants Toshiaki Itagaki - EVP and CFO Minoru Hirose - Head, R&D Portfolio Management Department Shinji Hidaka - General Manager, Marketing and Sales Conference ...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2020 Q1 earnings Read more ...

Drivers of the multi-year underperformance US Healthcare is the 2nd largest equity sector, with a 14% index weight , and has been a perennial underperformer the last five years (see chart), and lagged by 10 points last year alone. This was even as the sector has continued to post robust g...

Verastem, Inc. ( VSTM ) had a rough 2019 with a disappointing launch for COPIKTRA and the share price reacted accordingly. Recently, the company publicized that they closed a global licensing agreement with Chugai Pharmaceutical ( CHGCF ) to acquire the worldwide development and commercializ...

Verastem (NASDAQ: VSTM ) is up  14%  premarket on  announcing a global licensing agreement with Chugai Pharmaceutical ( OTCPK:CHGCF ) to obtain worldwide development and commercialization rights for RAF/MEK inhibitor CH5126766 (CKI27) from Chugai currently under development f...

Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2019 Earnings Conference Call July 25, 2019, 08:00 AM ET Company Participants Osamu Okuda - Executive VP and Co-Head of Project, Lifecycle Management Unit & Foundation Medicine Tatsuro Kosaka - President & CEO Toshiaki Itagaki - ...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings Read more ...

Chugai Pharmaceutical ( OTCPK:CHGCF ): 1H GAAP EPS of ¥126.35. More news on: Chugai Pharmaceutical Co., Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...